The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis Micaela AlmeidaMafalda SoaresLuísa Pereira Review 19 November 2019 Pages: 523 - 532
Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis Yan LiYidong ZhouQiang Sun Review 21 December 2019 Pages: 533 - 542
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies Natasha TraceyHelen CreedonValerie G. Brunton Preclinical study Open access 08 November 2019 Pages: 543 - 555
Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer Sasagu KurozumiSami AlsaeedEmad A. Rakha Preclinical study 09 November 2019 Pages: 557 - 564
Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis Satu TiainenAmro MasarwahPäivi Auvinen Preclinical study Open access 12 November 2019 Pages: 565 - 575
Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model Katherine Drews-ElgerAna Cristina Sandoval-LeonMarc E. Lippman Preclinical study 13 November 2019 Pages: 577 - 584
The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer Aileen I. FernandezXue GengRebecca B. Riggins Preclinical Study 19 November 2019 Pages: 585 - 604
Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients Yifan WuTao OuyangYuntao Xie Preclinical study 25 November 2019 Pages: 605 - 614
Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously Ling-Wei HiiFelicia Fei-Lei ChungChee-Onn Leong Preclinical study 29 November 2019 Pages: 615 - 629
TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties Kelly Kyker-SnowmanRobert M. HughesBen Ho Park Preclinical study 10 December 2019 Pages: 631 - 642
Evaluation of the anti-Thomsen–Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer Sabine HeubleinMarkus EggerNina Ditsch Preclinical study 11 December 2019 Pages: 643 - 652
Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice David R. MeierMegan A. GirtmanParaic A. Kenny Preclinical study 14 December 2019 Pages: 653 - 660
Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough? Laura H. RosenbergerYi RenJennifer K. Plichta Clinical trial 18 November 2019 Pages: 661 - 670
Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions Nicole Look HongFrances C. WrightAnanth Ravi Clinical trial Open access 21 November 2019 Pages: 671 - 676
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer Anouk K. M. ClaessensReinier Timmanthe Dutch Breast Cancer Research Group (BOOG) Clinical trial Open access 28 November 2019 Pages: 677 - 685
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older Min Hwan KimGun Min KimJoohyuk Sohn Clinical trial 06 December 2019 Pages: 687 - 697
25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival Charlotte KanstrupDorthe TeilumMathias Kvist Mejdahl Epidemiology 09 November 2019 Pages: 699 - 708
Weight trajectories in women receiving systemic adjuvant therapy for breast cancer Kirsten A. NyropAllison M. DealHyman B. Muss Epidemiology 16 November 2019 Pages: 709 - 720
Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information A. FrisellJ. LagergrenJ. de Boniface Epidemiology Open access 18 November 2019 Pages: 721 - 729
Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39 Ekaterina S. KuliginaAnna P. SokolenkoEvgeny N. Imyanitov Epidemiology 21 November 2019 Pages: 731 - 742
Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort Julie Louise Munk AndersenLouise HansenAnja Olsen Epidemiology 26 November 2019 Pages: 743 - 753
Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology Jean L. BrowneLilian CasasM. Angela Pascual Epidemiology 27 November 2019 Pages: 755 - 762
Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment? Kadri Altundag Letter to the Editor 14 December 2019 Pages: 763 - 763
Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery? Darko ZdravkovicMiroslav GranicBogdan Crnokrak Letter to the Editor 17 December 2019 Pages: 765 - 765
Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer Hong-Lin ChenLin DuXiao-Min Li Letter to the Editor 19 December 2019 Pages: 767 - 768
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy Suzanne E. WardellAlexander P. YllanesDonald P. McDonnell Correction Open access 16 November 2019 Pages: 769 - 769